Navidea reports promising results for beta-amyloid agent

07/23/2013 | News-Medical.Net

Navidea Biopharmaceuticals' NAV4694 beta-amyloid imaging candidate has demonstrated promising performance in a new study, according to the company. Researchers compared the agent with C-11 Pittsburgh Compound B in postmortem examinations of brain tissue. "This study indicated that unlike PiB, the benchmark PET amyloid agent, NAV4694 was capable of differentiating controls from AD in all brain regions and also exhibited a wider dynamic range and fewer false negatives as compared to gold-standard pathology," said researcher Dr. Pedro Rosa-Neto.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ